An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread

Allocation: The Microsatellite Instability High (MSI-High) and C4 and C6 Cohort Parts of the
trial are Non-randomized, The Non-MSI high Dose Escalation Phase part of the trial contained
a randomized portion

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Men and women ≥ 18 years of age

- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

- Histologically confirmed recurrent or metastatic colorectal cancer

- Measurable disease by CT or MRI

- Testing for MSI Status (by an accredited lab)

1. Subjects with microsatellite instability high (MSI-H) tumors will enroll in the
MSI-H Cohort (mStage and cStage groups), the C3 Cohort, and the C5 Cohort.

2. Subjects with phenotypes that are non-microsatellite instability high (non-MSI-H)
will enroll in the non- MSI-H Safety Cohort and the C6, C4 Cohorts.

- Adequate organ function as defined by study-specific laboratory tests

- Must use acceptable form of birth control throughout the study. After the final dose
of study drug, an acceptable form of birth control must be used for 23 weeks for women
of childbearing potential (WOCBP) and 31 weeks for men who are sexually active with
WOCBP

- Signed informed consent

- Willing and able to comply with study procedures

- Subjects enrolled into the C3 Cohort must have not had treatment for their metastatic
disease

Exclusion Criteria:

- Active brain metastases or leptomeningeal metastases are not allowed.

- Prior treatment with an anti-Programmed Death Receptor (PD)-1, anti-PD-L1, anti-PD-L2,
anti-Cytotoxic T-Cell Lymphoma-4 Antigen (CTLA-4) antibody, or any other antibody or
drug specifically targeting T-cell co-stimulation or immune checkpoint pathways

- Prior malignancy active within the previous 3 years except for locally curable cancers

- Subjects with active, known or suspected autoimmune disease

- Subjects with a condition requiring systemic treatment with either corticosteroids or
other immunosuppressive medications within 14 days of study drug administration

Other protocol defined inclusion/exclusion criteria could apply